Some implications of genetic biomarkers in occupational epidemiology and practice

Scandinavian Journal of Work, Environment and Health

Volumn 30, Issue 1, 2004, Pages 71-79

  Schulte, P A ^a  

^a NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

Author keywords

Epidemiology; Ethics; Genetic testing; Genetics; Genomics; Molecular epidemiology; Polymorphisms

Indexed keywords

BERYLLIUM; BIOLOGICAL MARKER; ETHYLENE OXIDE; GLUTAMIC ACID; GLUTATHIONE TRANSFERASE; HLA DP ANTIGEN; LEUKOCYTE ANTIGEN; PERIPHERAL MYELIN PROTEIN 22;

BIOMARKER; EPIDEMIOLOGY; METHODOLOGY; OCCUPATIONAL EXPOSURE;

ARTICLE; BERYLLIOSIS; CARPAL TUNNEL SYNDROME; CHROMOSOME 17; CLINICAL PRACTICE; GENE DELETION; GENETIC CODE; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; HEALTH PRACTITIONER; HEMATOLOGIC MALIGNANCY; HUMAN; INDUSTRIAL WORKER; MEDICAL ETHICS; MEDICAL SPECIALIST; OCCUPATIONAL CANCER; OCCUPATIONAL DISEASE; PENETRANCE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; VALIDATION PROCESS;

EID: 1442302289     PISSN: 03553140     EISSN: None     Source Type: Journal    
DOI: 10.5271/sjweh.767     Document Type: Article

References (84)

1. Gust ID, Lewis FA, Lehmann NI. Prevalence of antibody to hepatitis A and polioviruses in an unimmunized urban population. Am J Epidemiol 1978;107:54-6.
2. Truett J, Cornfield J, Kannel W. A multivariate analysis of coronary heart disease in Framingham. J Chronic Dis 1967; 20:511-24.
3. UK collaborative study on the alpha-fetoprotein screening for neural tube defects: maternal serum alpha-fetoprotein measurement in antenatal screening for anencephaly and spina bifida in early pregnancy. Lancet 1977;1:1323-32.
4. Baker EL, Landrigan PJ, Barbour DH, Cox DH, Folland DS, Ligo RN. Occupational lead poisoning in the United States: clinical and biochemical findings related to blood lead level. Br J Ind Med 1979;36:314-22.
5. Kilbourne ED. The molecular epidemiology of influenza. J Infect Dis 1973;127:478-87.
6. Schulte PA, Perera FP, editors. Molecular epidemiology: principles and practices. San Diego (CA): Academic Press Inc; 1993.
7. Morton NE. Outline of Genetic Epidemiology. New York (NY): Karger; 1982.
8. Khoury MJ, Dorman JS. The human genome epidemiology network. Am J Epidemiol 1998;148:1-3.
9. Pearce N. Traditional epidemiology, modem epidemiology and public health. Am J Public Health 1996;86:678-83.
10. Pang T. The impact of genomics on global health. Am J Public Health 2002;92:1077-9.
11. Holtzman NA, Andrews LB. Ethical and legal issues in genetic epidemiology. Epidemiol Rev 1997;19:163-74.
12. Davison C, MacIntyre S, Smith GD. The potential social impact of predictive genetic testing for susceptibility to common chronic diseases: a review and proposed agenda. Sociol Health Illness 1994;16:340-71.
13. Schulte PA, Lomax GP, Ward EM, Colligan MJ. Ethical issues in the use of genetic markers in occupational epidemiologic research. J Occup Environ Med 1999;41:639-46.
14. Rothstein MA, editor. Genetic Secrets: protecting privacy and confidentiality in the genetic era. New Haven (CT): Yale University Press; 1997.
15. Strudler A. The social construction of genetic abnormality: ethical implications for managerial decisions in the workplace. J Bus Ethics 1994;13:839-48.
16. Khoury MJ, Burke W, Thompson EJ, editors. Genetics and public health in the 21st century. Oxford: Oxford University Press; 2000.
17. Lappe M. Ethical issues in testing for differential sensitivity to occupational hazards. J Occup Med 1983;25:797-808.
18. Ashford NA. Medical screening in the workplace: legal and ethical considerations. Semin Occup Med 1986:1:67-79.
19. Lemmens T. What about your genes?: ethical, legal and policy dimensions of genetics in the workplace. Polit Life Sci 1997;16:57-75.
20. Omenn FS. Predictive identification of hypersusceptible individuals. J Occup Med 1982;24:369-74.
21. Austin MA. Ethical issues in human genome epidemiology: a case study based on the Japanese American Family Study in Seattle, Washington. Am J Epidemiol 2002;155:585-92.
22. Vineis P, Schulte P, McMichael AJ. Misconceptions about the use of genetic tests in populations. Lancet 2001;357:709-12.
23. Gostin LO, Hodge JG. Genetic privacy and the law: an end to genetics exceptionalism. Jurimetrics J 1999;40:21-58.
24. National Research Council. Biological markers in environmental health research. Environ Health Perspect 1987;74:1-19.
25. International Programme on Chemical Safety (IPCS). Environmental health critique biomarkers and risk assessment; concepts and principles. Geneva: World Health Organization, IPCS; 1993.
26. Medical Research Council (MRC). The use of biomarkers in environmental exposure assessment. Leicester (United Kingdom): Institute for Environment and Health, Medical Research Council; 1996. Report R5.
27. Vineis P, Malats N, Lang M, d'Errico A, Caporaso N, Cuzick J, et al, editors. Metabolic polymorphisms and susceptibility to cancer.. Lyon: International Agency for Research on Cancer (IARC); 1999. IARC scientific publishing, no 148.
28. Khoury MJ. Genetics and genomics in practice: the continuum from genetic disease to genetic information in health and disease. Genet Med 2003;5:261-8.
29. International Agency for Research on Cancer (IARC). Some industrial chemicals. Lyon: IARC; 1994. IARC monographs on the evaluation of carcinogenic risks to humans, vol 60.
30. Yong LC, Schulte PA, Wiencke JK, Boeniger MF, Connally LB, Walker JT, et al. Hemoglobin adducts and sister chromatid exchanges in hospital workers exposed to ethylene oxide: effects of glutathione-S-transferase T1 and M1 genotypes. Cancer Epidemiol Biomarkers Prev 2001;10:538-50.
31. Fost U, Hallier E, Ottenwalder H, Bolt HM, Peter H. Distribution of ethylene oxide in human blood and its implication for biomonitoring. Hum Exp Toxicol 1991;10:25-31.
32. Fost U, Tornqvist M, Leutbecher M, Granath F, Hallier E, Ehrenberg L. Effects of variation in detoxification rate on dose monitoring through adducts. Hum Exp Toxicol 1995; 14:201-3.
33. Beskow LM, Burke W, Merz JP, Barr PA, Penchaszadeh VB, Gostin LO, et al. Informed consent for population-based research involving genetics. JAMA 2001;286:2315-21.
34. National Bioethics Advisory Commission (NBAC). Research involving human biological materials: ethical issues and policy guidance. Vol 1. Rockville (MD): NBAC; 1999. http://www.bioethic.gov. Accessed July, 1999.
35. Weeks JL, Levy BS, Wagner GR, editors. Preventing occupational disease and injury. Washington (CD): American Public Health Association; 1991. p 45-51.
36. Richeldi L, Sorrentino R, Saltini C. HLA-DPBI glutamate 69: a genetic marker of beryllium disease. Science 1993 Oct 8;262(5131):197-8.
37. Wang Z, White DS, Petrovic M, Tatum OL, Newman LS, Maier LA, et al. Differential susceptibilities to chronic beryllium disease contributed by different Glu 69 HLA-DPB1 and -DPA1 alleles. J Immunol 1999;163(3):1647-53.
38. Saltini C, Richeldi L, Losi M, Amicosante M, Voorter C, van den Berg-Lonen E, et al. Major histocompatibility locus genetic markers of beryllium sensitization and disease. Eur Respir J 2001;18(4):677-84.
39. Weston A, Ensey J, Kreiss K, Keshava C, McCanlies E. Racial differences in prevalence of a supratypic HLA genetic marker immaterial to pre-employment testing for susceptibility to chronic beryllium disease. Am J Ind Med 2002;41:457-65.
40. Murray TH. Genetic exceptionalisin and "future diaries": is genetic information different from other medical information. In: Rothstein MA, editor. Genetic secrets: protecting privacy and confidentiality in the genetic era. New Haven (CT): Yale University Press; 1997:60-73.
41. Rothenberg K, Fuller B, Rothstein M, Duster T, Ellis Kahn MJ, Cunningham R, et al. Genetic information and the workplace: legislative approaches and policy challenges. Science 1997;275:1755-7.
42. Hall MA. Insurers use of genetic information. Jurimetrics 1996;7:13-22.
43. Bingham E. Ethical issues of genetic testing for workers. In: Mendelsohn ML, Mohr LC, Peeters JP, editors. Biomarkers: medical and workplace applications. Washington (CD): John Henry Press; 1998:415-22.
44. Draper E. Risky business: genetic testing and exclusionary practices in the hazardous workplace. Cambridge (UK): Cambridge University Press; 1991.
45. United States District Court, Northern District of Iowa: US EEOC. Burlington Northern Santa Fe Railway Company. Civ NO C01-4013 MWB, EEOC's memorandum in support of petition for a preliminary injunction. February 8, 2001.
46. Chance PF. Overview of hereditary neuropathy with liability to pressure palsies. Ann NY Acad Sci 1999 Sep 14;883:14-21.
47. Schulte PA, Lomax G. Assessment of the scientific basis for genetic testing of railroad workers with carpal tunnel syndrome. J Occup Environ Med 2003;45:592-600.
48. Giersiepen K, Eberle A, Pohlabern H. Gender differences in carpal tunnel syndrome: occupational and non-occupational risk factors in a population-based case-control study. Ann Epidemiol 2000;10:481.
49. National Academy of Sciences. Work-related musculoskeletal disorders: report, workshop, summary, and workshop papers. Washington (CD): National Academy of Sciences, National Research Council; 1999. OSHA exhibit no 26-37.
50. National Institute for Occupational Safety and Health (NIOSH). Musculoskeletal disorder and workplace factors: a critical review of epidemiologic evidence for work-related musculoskeletal disorders of the neck, upper extremity, and low back. Washington (DC): US Department of Health and Human Services; 1997. DHHS (NIOSH) publication no 97-141.
51. Radecki P. The familial occurrence of carpal tunnel syndrome. Muscle Nerve 1994;17:325-30.
52. American College of Medical Genetics. Points to consider in preventing unfair discrimination on genetic disease risk: a position statement of the America College of Medical Genetics. Genet Med 2001;3:436-7.
53. US Task Force on Genetic Testing. Promoting safe and effective genetic testing in the United States. Baltimore (MD): Johns Hopkins University Press; 1998.
54. Burke W, Atkins D, Gwinn M, Gutmacher A, Haddow J, Lau J, et al. Genetic test evaluation: information needs of clinicians, policy makers and the public. Am J Epidemiol 2002:156:311-8.
55. Wald N, Cuckle H. Reporting the assessment of screening and diagnostic tests. Br J Obstet Gynaecol 1989;96(4):389-96.
56. Weincke JK, Pemble S, Ketter B, Kelsey KT. Gene deletion of glutathione S-transferase theta: correlation with induced genetic damage and potential role in endogenous mutagenesis. Cancer Epidemiol Biomarkers Prev 1995;4:253-9.
57. Pemble S, Schroeder KR, Spencer SR, Meyer DJ, Hallier E, Bolt HM, et al. Human glutathione S-transferase theta (GSTT1): c DNA cloning and the characterization of a genetic polymorphism. Biochem J 1994;300:271-6.
58. Sorrentino R, Potolicchio I, Ferrara GB, Tosi R. A new approach to HLA-DPB1 typing combining DNA heteroduplex analysis with allele-specific amplifications and enzyme restriction. Immunogenetics 1992;36:248-54.
59. Clayton EW, Steinberg KK, Khoury MJ. Informal consent for genetic research on stored tissue samples. JAMA 1995;274:1786-92.
60. King HC, Sinha AA. Gene expression profile analysis by DNA microarrays: promise and pitfalls. JAMA 2001; 286:2280-8.
61. Tennant RW. The National Center for Toxicogenomics: Using new technologies to inform mechanistic toxicology. Environ Health Perspect 2002;110:A-8-10.
62. Henry CJ, Phillips R, Carpanini F, Corton JC, Craig K, Iqarashi K, et al. Use of genomics in toxicology and epidemiology: findings and recommendations of a workshop. Environ Health Perspect 2002;110:1047-50.
63. Millikan R. The changing face of epidemiology in the genomics era. Epidemiology 2002;13:472-80.
64. Mostowy S, Behr MA. Comparative genomics in the fight against tuberculosis: diagnostics, epidemiology, and BCG vaccination. Am J Pharmacogenomics 2002;2(3):189-96.
65. Shpilberg O, Dorman JS, Ferrell RE, Trucco M, Shahar A, Kuller LH. The next stage: molecular epidemiology. J Clin Epidemiol 1997;50:633-8.
66. Begg CB. The search for cancer risk factors: when can we stop looking? Am J Public Health 2001;91:360-4.
67. Rockhill B, Kawachi I, Colditz GA. Individual risk prediction and population-wide disease prevention. Epidemiol Rev 2000;22:176-80.
68. Rose G. Strategy of prevention: lessons from cardiovascular disease. BMJ (Clin Res Ed) 1981;282:1847-51.
69. Holtzman NA, Marteau TM. Will genetics revolutionize medicine. New Eng J Med 2000;343:141-4.
70. Davey Smith G, Ebrahim S. 'Mendelian Randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 2003;32:1-22.
71. Rothman N, Wacholder S, Caporaso NE, Garcia-Closas M, Buetow K, Fraumeni JF. The use of common genetic polymorphisms to enhance the epidemiologic study of environmental carcinogens. Biochem Biophysic Act 2001;1471:C1-C10.
72. Maojo V, Kulikowski CA. Bioinformatics and medical informatics: collaboration on the road to genomic medicine? J Am Med Inform Assoc 2003 [Epub ahead of print]. Published August 4, 2003 as doi:10.1197/jamia.M1305.
73. Weiss KM, Terwilliger JD. How many diseases does it take to map a gene with SNPs? Nat Genet 2000;26:151-7.
74. Taubes G. Epidemiology faces its limits. Science 1995;269:164-9.
75. Davey Smith G. Reflections on the limitations to epidemiology. J Clin Epidemiol 2001;54:325-31.
76. Little J, Khoury MJ. Mendelian randomization: a new spin or real progress? Lancet 2003;362:930-1.
77. Cherry N, Mackness M, Durrington P, Povey A, Dippnall M, Smith T, et al. Paroxanase (PON1) polymorphisms in farmers attributing ill health to sheep dip. Lancet 2002;359:763-4.
78. Rundle A, Schwartz S. Issues in epidemiological analysis and interpretation of intermediate biomarkers. Cancer Epidemiol Biomarkers Prev 2003;12:497-502.
79. Kelada SN, Eaton DL, Wang SS, Rothman NR, Khoury MJ. The role of genetic polymorphisms in environmental health. Environ Health Perspect 2003;111:1055-64.
80. Brennan P. Gene-environment interaction and the aetiology of cancer: what does it mean and how can we measure it? Carcinogenesis 2002;23:381-7.
81. Liotta L, Kohn EC, Petricoin EF. Clinical proteomics: personalized molecular medicine. JAMA 2001;286:2211-14.
82. Ahsan H, Rundle AG. Measures of genotype versus products: promise and pitfalls in cancer prevention. Carcinogenesis 2003;24:1429-34.
83. Merikangas KR, Risch N. Genomic priorities and public health. Science 2003;302:599-601.
84. Khoury MJ. Epidemiology and the continuum from genetic research to genetic testing. Am J Epidemiol 2002;156:297-9.